GILD Live signaler | Maksimer profitt med Getagraph.com

SELG 483 min ago

@ $64.70

Utstedt: 3 mai 2024 @ 17:43

Avkastning: 0.12%

Forrige signal: mai 3 - 15:35

Forrige signal: Kjøp

Avkastning: -0.25 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Our systems believe the stock currently is overvalued by 0.06% compare to its pairs and should correct downwards.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
Dagens volum	7.75M
Gjennomsnittsvolum	7.40M
Markedsverdi	80.78B
EPS	$0 ( 2024-04-25 )
Neste inntjeningsdato	( $1.590 ) 2024-08-01
Last Dividend	$0.750 ( 2023-12-14 )
Next Dividend	$0 ( N/A )
P/E	179.94
ATR14	$1.200 (1.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Telman Deborah H	Sell	515	Restricted Stock Unit
2024-04-25	Telman Deborah H	Buy	515	Common Stock
2024-04-25	Telman Deborah H	Sell	158	Common Stock
2024-04-01	Parsey Merdad	Sell	2 000	Common Stock
2024-03-28	Lofton Kevin E	Buy	34	Phantom Stock

INSIDER POWER
62.13
Last 99 transactions
Buy: 1 291 503 \| Sell: 311 301

Korrelasjon (AI algo v.1.1b): Overvalued: -0.06% $64.70 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.24 (neutral)

Kort: -0.51 (weak negative)

Signal:(53) Neutral

Gilead Sciences Inc Korrelasjon

10 Mest positive korrelasjoner
NUTX	0.956
TROO	0.95
PRTA	0.943
SINT	0.941
RNW	0.931
APLD	0.93
DCFC	0.928
PTON	0.928
BNTX	0.926
MRBK	0.923

10 Mest negative korrelasjoner
FAAR	-0.946
ADES	-0.941
BOCN	-0.928
RAM	-0.921
AMTBB	-0.917
CITE	-0.917
BCSA	-0.915
XENT	-0.915
XFIN	-0.914
IXAQ	-0.914

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Gilead Sciences Inc Korrelasjon - Valuta/Råvare

0.08
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.32
( neutral )

-0.10
( neutral )

Gilead Sciences Inc Økonomi

Annual	2023
Omsetning:	$27.12B
Bruttogevinst:	$21.15B (77.99 %)
EPS:	$4.54

FY	2023
Omsetning:	$27.12B
Bruttogevinst:	$21.15B (77.99 %)
EPS:	$4.54

FY	2022
Omsetning:	$27.28B
Bruttogevinst:	$21.62B (79.26 %)
EPS:	$3.66

FY	2021
Omsetning:	$27.31B
Bruttogevinst:	$20.70B (75.82 %)
EPS:	$4.96

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.730 (N/A)	$0.730 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Gilead Sciences Inc Dividend Information - Dividend King

Dividend Sustainability Score: 9.34 - good (93.42%) | Divividend Growth Potential Score: 6.34 - Stable (26.81%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.430	2015-06-12
Last Dividend	$0.750	2023-12-14
Next Dividend	$0	N/A
Payout Date	2023-12-28
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	$21.49	--
Avg. Dividend % Per Year	2.65%	--
Score	5.26	--
Div. Sustainability Score	9.34
Div.Growth Potential Score	6.34
Div. Directional Score	7.84	--

Next Divdend (Est)
(2024-07-01)

$0.764 Estimate 39.70 %

Dividend Stability

0.79 Good

Dividend Score

5.26

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$1.290	1.36%
2016	$1.840	1.88%
2017	$2.08	2.80%
2018	$2.28	3.08%
2019	$2.52	3.97%
2020	$2.72	4.17%
2021	$2.84	4.72%
2022	$2.92	4.02%
2023	$3.00	3.51%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0176	1.500	9.65	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00860	1.200	9.71	10.00	[0 - 0.3]
returnOnEquityTTM	0.0232	1.500	-0.854	-1.280	[0.1 - 1]
payoutRatioTTM	5.87	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.980	0.800	-0.102	-0.0814	[1 - 3]
quickRatioTTM	1.084	0.800	8.33	6.66	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.459	-1.500	2.35	-3.53	[0 - 0.6]
interestCoverageTTM	9.53	1.000	7.58	7.58	[3 - 30]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.34	2.00	6.83	10.00	[0 - 20]
debtEquityRatioTTM	1.479	-1.500	4.08	-6.12	[0 - 2.5]
grossProfitMarginTTM	0.777	1.000	0.382	0.382	[0.2 - 0.8]
operatingProfitMarginTTM	0.336	1.000	5.28	5.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.328	1.000	9.29	9.29	[0.2 - 2]
assetTurnoverTTM	0.488	0.800	-0.0824	-0.0659	[0.5 - 2]
Total Score				9.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	168.32	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0232	2.50	-0.549	-1.280	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.34	2.00	7.89	10.00	[0 - 30]
dividendYielPercentageTTM	4.62	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	5.87	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.570	1.500	9.54	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.309	1.000	4.78	0	[0.1 - 0.5]
Total Score				6.34

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.